- Home
- PETS vs CPIX Comparison
PETS vs CPIX Comparison
Compare PETS & CPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETS
- CPIX
- Stock Information
- Founded
- PETS 1996
- CPIX 1999
- Country
- PETS United States
- CPIX United States
- Employees
- PETS N/A
- CPIX N/A
- Industry
- PETS Retail-Drug Stores and Proprietary Stores
- CPIX Biotechnology: Pharmaceutical Preparations
- Sector
- PETS Consumer Staples
- CPIX Health Care
- Exchange
- PETS Nasdaq
- CPIX Nasdaq
- Market Cap
- PETS 57.8M
- CPIX 51.5M
- IPO Year
- PETS N/A
- CPIX 2009
- Fundamental
- Price
- PETS $1.99
- CPIX $2.15
- Analyst Decision
- PETS Sell
- CPIX
- Analyst Count
- PETS 1
- CPIX 0
- Target Price
- PETS $3.20
- CPIX N/A
- AVG Volume (30 Days)
- PETS 176.5K
- CPIX 59.5K
- Earning Date
- PETS 11-03-2025
- CPIX 11-04-2025
- Dividend Yield
- PETS N/A
- CPIX N/A
- EPS Growth
- PETS N/A
- CPIX N/A
- EPS
- PETS N/A
- CPIX N/A
- Revenue
- PETS $226,972,000.00
- CPIX $41,278,349.00
- Revenue This Year
- PETS N/A
- CPIX N/A
- Revenue Next Year
- PETS $2.98
- CPIX N/A
- P/E Ratio
- PETS N/A
- CPIX N/A
- Revenue Growth
- PETS N/A
- CPIX 12.21
- 52 Week Low
- PETS $1.93
- CPIX $1.04
- 52 Week High
- PETS $6.85
- CPIX $7.25
- Technical
- Relative Strength Index (RSI)
- PETS 34.39
- CPIX 29.34
- Support Level
- PETS $1.93
- CPIX $1.93
- Resistance Level
- PETS $2.92
- CPIX $2.23
- Average True Range (ATR)
- PETS 0.16
- CPIX 0.22
- MACD
- PETS -0.04
- CPIX -0.08
- Stochastic Oscillator
- PETS 6.57
- CPIX 14.97
About PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About CPIX Cumberland Pharmaceuticals Inc.
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.